National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15–69 years in Mongolia in 2019

The aim of the study was to evaluate the prevalence, distribution and correlates of dyslipidaemia among people (15–69 years) in Mongolia. National data were analyzed from 4,895 individuals (15–69 years, median age = 35 years) that took part in the Mongolia cross-sectional STEPS survey in 2019, and h...

Full description

Saved in:
Bibliographic Details
Main Authors: Supa Pengpid, Karl Peltzer
Other Authors: Asia University
Format: Article
Published: 2022
Subjects:
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/75384
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University
id th-mahidol.75384
record_format dspace
spelling th-mahidol.753842022-08-04T11:56:56Z National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15–69 years in Mongolia in 2019 Supa Pengpid Karl Peltzer Asia University University of the Free State Mahidol University Multidisciplinary The aim of the study was to evaluate the prevalence, distribution and correlates of dyslipidaemia among people (15–69 years) in Mongolia. National data were analyzed from 4,895 individuals (15–69 years, median age = 35 years) that took part in the Mongolia cross-sectional STEPS survey in 2019, and had complete lipid measurements. Dyslipidaemia was defined using the guidelines of the Adult Treatment Panel III. The prevalence of dyslipidaemia was 58.6%, 31.7% high triglycerides (TG), 26.9% high low-density lipoprotein cholesterol (LDL-C), 26.9% high total cholesterol (TC) and 14.6% low high-density lipoprotein cholesterol (HDL-C). Among those with dyslipidaemia, 6.2% were aware. Among those who were aware, the proportion of lipid-lowering drug treatment was 18.9% and among those who took lipid-lowering drugs, 21.5% had their dyslipidaemia controlled. In adjusted logistic regression, older age (40–69 years) (AOR: 1.19, 95% CI 1.02–1.40), urban residence (AOR: 1.24, 95% CI 1.04–1.48), obesity call II (AOR: 2.89, 95% CI 2.29–3.66), hypertension (AOR: 1.33, 95% CI 1.11–1.59), and diabetes (AOR: 1.62, 95% CI 1.20–2.18) were positively, and male sex (AOR: 0.84, 95% CI 0.72–1.00) was negatively associated with dyslipidaemia prevalence. Six in ten Mongolians 15 years and older had dyslipidaemia. Several factors associated with dyslipidaemia that can be used to target public health interventions were identified. 2022-08-04T04:56:56Z 2022-08-04T04:56:56Z 2022-12-01 Article Scientific Reports. Vol.12, No.1 (2022) 10.1038/s41598-022-14729-2 20452322 2-s2.0-85132179593 https://repository.li.mahidol.ac.th/handle/123456789/75384 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85132179593&origin=inward
institution Mahidol University
building Mahidol University Library
continent Asia
country Thailand
Thailand
content_provider Mahidol University Library
collection Mahidol University Institutional Repository
topic Multidisciplinary
spellingShingle Multidisciplinary
Supa Pengpid
Karl Peltzer
National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15–69 years in Mongolia in 2019
description The aim of the study was to evaluate the prevalence, distribution and correlates of dyslipidaemia among people (15–69 years) in Mongolia. National data were analyzed from 4,895 individuals (15–69 years, median age = 35 years) that took part in the Mongolia cross-sectional STEPS survey in 2019, and had complete lipid measurements. Dyslipidaemia was defined using the guidelines of the Adult Treatment Panel III. The prevalence of dyslipidaemia was 58.6%, 31.7% high triglycerides (TG), 26.9% high low-density lipoprotein cholesterol (LDL-C), 26.9% high total cholesterol (TC) and 14.6% low high-density lipoprotein cholesterol (HDL-C). Among those with dyslipidaemia, 6.2% were aware. Among those who were aware, the proportion of lipid-lowering drug treatment was 18.9% and among those who took lipid-lowering drugs, 21.5% had their dyslipidaemia controlled. In adjusted logistic regression, older age (40–69 years) (AOR: 1.19, 95% CI 1.02–1.40), urban residence (AOR: 1.24, 95% CI 1.04–1.48), obesity call II (AOR: 2.89, 95% CI 2.29–3.66), hypertension (AOR: 1.33, 95% CI 1.11–1.59), and diabetes (AOR: 1.62, 95% CI 1.20–2.18) were positively, and male sex (AOR: 0.84, 95% CI 0.72–1.00) was negatively associated with dyslipidaemia prevalence. Six in ten Mongolians 15 years and older had dyslipidaemia. Several factors associated with dyslipidaemia that can be used to target public health interventions were identified.
author2 Asia University
author_facet Asia University
Supa Pengpid
Karl Peltzer
format Article
author Supa Pengpid
Karl Peltzer
author_sort Supa Pengpid
title National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15–69 years in Mongolia in 2019
title_short National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15–69 years in Mongolia in 2019
title_full National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15–69 years in Mongolia in 2019
title_fullStr National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15–69 years in Mongolia in 2019
title_full_unstemmed National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15–69 years in Mongolia in 2019
title_sort national high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15–69 years in mongolia in 2019
publishDate 2022
url https://repository.li.mahidol.ac.th/handle/123456789/75384
_version_ 1763493771849236480